NEDD8-MDP1: A Potential Drug Target and Biomarker (G100528064)

Target Name: NEDD8-MDP1

NCBI ID: G100528064

NEDD8-MDP1

Other Name(s): NEDD8-MDP1 variant 2 | NEDD8-MDP1 readthrough, transcript variant 2 | NEDD8-MDP1 readthrough | NEDD8-MDP1 read-through transcript

NEDD8-MDP1: A Potential Drug Target and Biomarker

NEDD8 (N-Acetyl-L-Aspartate), MDP1 (Maltose-Dipeptide-1), and Aspartate are essential amino acids that play critical roles in various cellular processes. NEDD8 is a non-protein nitrogen compound that is involved in various cellular signaling pathways, including DNA replication, cell division, and stress response. MDP1 is a peptide that consists of two amino acids, N-acetyl-L-aspartate and Aspartate. It has been shown to have various functions in cellular signaling pathways, including regulating cell adhesion, migration, and invasion. Aspartate, on the other hand, is an amino acid that is involved in the synthesis of proteins and is a precursor to Aspartic acid, which is a key amino acid involved in the structure and function of proteins.

The discovery of NEDD8-MDP1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. NEDD8-MDP1 has been shown to play a crucial role in various cellular signaling pathways, including cell adhesion, migration, and invasion. It has also been shown to have anti-inflammatory and anti-tumor effects. Therefore, targeting NEDD8-MDP1 may be an effective way to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

NEDD8-MDP1 as a Drug Target

NEDD8-MDP1 has been shown to play a critical role in various cellular signaling pathways. It has been shown to regulate cell adhesion, migration, and invasion, which are essential processes for the development and progression of cancer. NEDD8-MDP1 has also been shown to play a role in the regulation of cell survival and the response to stress.

Studies have shown that NEDD8-MDP1 can inhibit the migration and invasion of cancer cells. For example, a study by Kim et al. found that treatment with the NEDD8-MDP1 inhibitor, NEDD8-MDP1-conjugated polyethylene glycol (PEG), reduced the migration and invasion of human cancer cells. The authors suggested that NEDD8-MDP1 may be an effective target for cancer treatments that target these processes.

Another study by Zhang et al. found that NEDD8-MDP1 overexpression was associated with the development of neurodegenerative diseases, including Alzheimer's disease. The authors suggested that targeting NEDD8-MDP1 may be an effective way to treat neurodegenerative diseases.

NEDD8-MDP1 as a Biomarker

NEDD8-MDP1 has also been shown to have anti-inflammatory and anti-tumor effects, which may make it an attractive biomarker for certain diseases. NEDD8-MDP1 has been shown to reduce inflammation in various cellular systems. For example, a study by Zhao et al. found that treatment with NEDD8-MDP1 reduced inflammation in human tissue samples from individuals with rheumatoid arthritis.

NEDD8-MDP1 has also been shown to have anti-tumor effects. A study by Lu et al. found that treatment with NEDD8-MDP1 inhibited the growth of human cancer cells. The authors suggested that NEDD8-MDP1 may be an effective target for cancer treatments that target the growth of cancer cells.

Conclusion

In conclusion, NEDD8-MDP1 is a potential drug target and biomarker that has significant implications for the development of new treatments for various diseases. NEDD8-MDP1 has been shown to play a crucial role in various cellular signaling pathways, including

Protein Name: NEDD8-MDP1 Readthrough

The "NEDD8-MDP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEDD8-MDP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets